B
Bull
Bull · 25%BRTX
$4.26
Szenariopreis
$0.199
-0.007 (-3.35%)Zum Schluss
Loading chart…
- High
- 0.219
- Open
- 0.219
- VWAP
- 0.20
- Vol
- 244.77K
- Mkt Cap
- 12.39M
- Low
- 0.197
- Amount
- 50.15K
- EV/EBITDA, TTM
- -0.01
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
AI analysis of BioRestorative Therapies Inc (BRTX)
sellBioRestorative Therapies Inc (BRTX) is not a good buy right now due to its current price of $0.20, which is down 83.68% year-to-date, and an RSI of 28.595 indicating it is oversold. The company has also reported significant net losses, with a net income of -2154405 USD in Q1 2026, which raises concerns about its financial health.
Bewertungskennzahlen
The current forward P/E ratio for BioRestorative Therapies Inc (BRTX) is 0.00, compared to its 5-year average forward P/E of -1.10.
Alphio AI Price Scenarios for BRTX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
5.006-18NewsfilterBioRestorative Appoints New VP to Drive Sales Expansion
8.505-29NASDAQ.COMRegulatory Approvals and Collaborations in Biotech Sector
9.005-27NASDAQ.COMBioRestorative Completes Phase 2 Trial for BRTX-100
9.005-26NASDAQ.COMBioRestorative Completes Patient Dosing in BRTX-100 Clinical Trial
- 2.005-26Newsfilter
BioRestorative Completes Phase 2 Trial for BRTX-100 in Chronic Lumbar Disc Disease
BRTX FAQ — answered by Alphio AI
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).
BioRestorative Therapies Inc (BRTX) is not a good buy right now due to its current price of $0.20, which is down 83.68% year-to-date, and an RSI of 28.595 indicating it is oversold. The company has also reported significant net losses, with a net income of -2154405 USD in Q1 2026, which raises concerns about its financial health.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.